ATE346922T1 - Domäne 1 beta2-gpi polypetiden und deren diagnostische und therepeutische verwendungen - Google Patents

Domäne 1 beta2-gpi polypetiden und deren diagnostische und therepeutische verwendungen

Info

Publication number
ATE346922T1
ATE346922T1 AT99937843T AT99937843T ATE346922T1 AT E346922 T1 ATE346922 T1 AT E346922T1 AT 99937843 T AT99937843 T AT 99937843T AT 99937843 T AT99937843 T AT 99937843T AT E346922 T1 ATE346922 T1 AT E346922T1
Authority
AT
Austria
Prior art keywords
domain
beta2gpi
polypeptides
polypetids
therepeutic
Prior art date
Application number
AT99937843T
Other languages
English (en)
Inventor
David M Marquis
Gilbert M Iverson
Edward J Victoria
David S Jones
Matthew D Linnik
Original Assignee
Jolla Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27376031&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE346922(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jolla Pharma filed Critical Jolla Pharma
Application granted granted Critical
Publication of ATE346922T1 publication Critical patent/ATE346922T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rehabilitation Therapy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
AT99937843T 1998-06-09 1999-06-09 Domäne 1 beta2-gpi polypetiden und deren diagnostische und therepeutische verwendungen ATE346922T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8865698P 1998-06-09 1998-06-09
US10308898P 1998-10-05 1998-10-05
US09/328,199 US6858210B1 (en) 1998-06-09 1999-06-08 Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same

Publications (1)

Publication Number Publication Date
ATE346922T1 true ATE346922T1 (de) 2006-12-15

Family

ID=27376031

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99937843T ATE346922T1 (de) 1998-06-09 1999-06-09 Domäne 1 beta2-gpi polypetiden und deren diagnostische und therepeutische verwendungen

Country Status (12)

Country Link
US (2) US6858210B1 (de)
EP (1) EP1092027B1 (de)
JP (1) JP2002517245A (de)
KR (1) KR20010052713A (de)
CN (1) CN1310759A (de)
AT (1) ATE346922T1 (de)
AU (1) AU772851B2 (de)
CA (1) CA2329942A1 (de)
DE (1) DE69934228T2 (de)
ES (1) ES2275348T3 (de)
PT (1) PT1092027E (de)
WO (1) WO1999064595A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268454A (en) 1991-02-08 1993-12-07 La Jolla Pharmaceutical Company Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
KR100361933B1 (ko) * 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
US6858210B1 (en) 1998-06-09 2005-02-22 La Jolla Pharmaceutical Co. Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
US6458953B1 (en) * 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
US6399578B1 (en) 1998-12-09 2002-06-04 La Jolla Pharmaceutical Company Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
CA2376057A1 (en) * 1999-06-08 2000-12-14 La Jolla Pharmaceutical Company Valency platform molecules comprising aminooxy groups
CN1382062A (zh) * 1999-07-29 2002-11-27 埃匹克斯医学股份有限公司 通过多位点结合的寻靶多体造影剂
CN1399562A (zh) * 1999-11-28 2003-02-26 拉卓拉药物公司 基于抗体亲和力来治疗狼疮的方法及使用这种方法的筛选方法和组合物
CA2414076A1 (en) * 2000-06-08 2001-12-13 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
ATE513854T1 (de) * 2000-12-13 2011-07-15 Bac Ip B V Proteinraster aus variablen domänen der schweren immunoglobulinkette von kamelen
TWI221406B (en) 2001-07-30 2004-10-01 Epix Medical Inc Systems and methods for targeted magnetic resonance imaging of the vascular system
US20030114405A1 (en) * 2001-08-13 2003-06-19 Linnik Matthew D. Methods of treating systemic lupus erythematosus in individuals having significantly impaired renal function
EP1534269B1 (de) * 2002-07-19 2013-10-30 The General Hospital Corporation Oxim-konjugate und verfahren zu ihrer bildung und verwendung
WO2004060320A2 (en) * 2002-12-27 2004-07-22 La Jolla Pharmaceutical Company Methods of improving health-related quality of life in individuals with systemic lupus erythematosus
DE10310082A1 (de) * 2003-03-07 2004-09-16 Ktb Tumorforschungsgesellschaft Mbh Protein-bindende Doxorubicin-Peptid-Derivate
WO2004089422A2 (en) * 2003-03-30 2004-10-21 La Jolla Pharmaceutical Co. Methods of treating and monitoring systemic lupus erythematosus in individuals
CN101146826A (zh) * 2005-01-24 2008-03-19 得克萨斯大学体系董事会 与磷脂酰丝氨酸结合的fc融合构建体及其治疗用途
US8017342B2 (en) 2005-04-18 2011-09-13 Bio-Rad Laboratories, Inc. Solid phase immobilization of phospholipids and cofactor proteins via covalent attachment
WO2008036449A2 (en) * 2006-06-29 2008-03-27 The Regents Of The University Of California Chemical antibodies for immunotherapy and imaging
US20080015145A1 (en) 2006-07-11 2008-01-17 Maria Gyongyossy-Issa Mimotope receptors and inhibitors for platelet-platelet and platelet-endothelium interactions
CN102272598B (zh) * 2009-01-02 2014-06-18 福升兴业股份有限公司 用以诊断自体免疫疾病之人工合成肽及试剂盒
WO2011163568A1 (en) 2010-06-24 2011-12-29 University Of Kansas Conjugates comprising an n-oxime bond and associated methods
CN105273080A (zh) * 2014-07-14 2016-01-27 于珮 一种还原型β2-糖蛋白Ⅰ的制备方法
US10098960B2 (en) 2015-04-03 2018-10-16 Ucl Business Plc Polymer conjugate
TWI572617B (zh) * 2016-01-20 2017-03-01 國立陽明大學 重組β－醣蛋白胜肽及其於抗腫瘤之應用
CN105801694A (zh) * 2016-05-03 2016-07-27 上海科新生物技术股份有限公司 一种抗心磷脂/β2糖蛋白I复合物的嵌合抗体
US11661447B2 (en) * 2017-08-03 2023-05-30 The Cleveland Clinic Foundation Human β2-glycoprotein I expression
WO2022195051A1 (en) * 2021-03-18 2022-09-22 Université De Genève Peptides and use thereof for diagnosing and treating antiphospholipid syndrome
CN115894270B (zh) * 2022-10-10 2024-09-06 深圳市迪克曼生物科技有限公司 一种神经酰胺及其制备方法和应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4191668A (en) 1977-02-03 1980-03-04 Scripps Clinic And Research Foundation Induction of immunological tolerance
US6022544A (en) 1983-01-24 2000-02-08 The John Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US5126131A (en) 1983-01-24 1992-06-30 The Johns Hopkins University Therapeutic suppression of specific immune responses by administration of antigen-competitive conjugates.
US5370871A (en) 1983-01-24 1994-12-06 The Johns Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US4650675A (en) 1983-08-18 1987-03-17 The Children's Medical Center Corporation Oligonucleotide conjugates
US4751181A (en) 1984-12-31 1988-06-14 Duke University Methods and compositions useful in the diagnosis and treatment of autoimmune diseases
DE3676670D1 (de) 1985-06-26 1991-02-07 Cetus Corp Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
WO1989009628A1 (en) 1988-04-04 1989-10-19 Potempa Lawrence A Binding of immune complexes by modified forms of c-reactive protein
EP0450099B1 (de) 1989-10-19 1996-09-11 Yamasa Shoyu Kabushiki Kaisha Träger zur bindung von antiphospholipid-antikörpern, diese antikörper verwendender immunotest und kit dafür
US5268454A (en) 1991-02-08 1993-12-07 La Jolla Pharmaceutical Company Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
US5162515A (en) 1990-01-16 1992-11-10 La Jolla Pharmaceutical Company Conjugates of biologically stable polymers and polynucleotides for treating systemic lupus erythematosus
US5552391A (en) 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
JPH04218000A (ja) 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
US5498538A (en) 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
WO1991015772A1 (en) 1990-04-06 1991-10-17 Yamasa Shoyu Co. Ltd. Methods for determining phospholipids and antibodies thereof
EP0572443A1 (de) 1990-12-17 1993-12-08 The Johns Hopkins University Unterdrückung von immunantworten durch oligomere formen von antigenen mit kontrollierter chemie
WO1993002093A1 (en) 1991-07-15 1993-02-04 La Jolla Pharmaceutical Company Modified phosphorous intermediates for providing functional groups on the 5' end of oligonucleotides
DE69322842T2 (de) 1992-02-05 1999-05-20 Koike, Takao, Sapporo, Hokkaido Festphasenreagenz und selbiges verwendendes antikörpertestverfahren
FR2701263B1 (fr) 1993-02-09 1995-04-21 Elie Stefas Procédé d'obtention d'une composition aqueuse protéinique, composition correspondante, glycoprotéine contenue et son utilisation pour la stabilisation de l'albumine et la détection ou le dosage d'anticorps.
ATE359830T1 (de) 1993-09-08 2007-05-15 Jolla Pharma Chemisch definierten nicht-polymer wertigen plattformmolokülen und ihren konjugaten
US5998223A (en) * 1993-11-16 1999-12-07 Yamasa Corporation Method of assaying autoimmune anticardiolipin antibody and kit therefor
FR2722991B1 (fr) 1994-08-01 1996-10-11 Orstom Utilisation de la beta2-glycoproteine i sous au moins une de ses formes comme agent anti-infectueux et composition pharmaceutique corrrespondante
JPH08333390A (ja) 1995-04-07 1996-12-17 Hoechst Japan Ltd ペプチド及びそれからなる自己免疫疾患治療剤
US5874409A (en) 1995-06-07 1999-02-23 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
US5780319A (en) 1996-04-19 1998-07-14 Pasteur Sanofi Diagnostics Immunoassays to detect antiphospholipid antibodies
KR20000016414A (ko) 1996-06-06 2000-03-25 와이즈먼 앤드루 Apl 면역반응성 펩티드, 그것의 콘주게이트 및 apl항체-매개병변의 치료방법
DE19637770A1 (de) 1996-09-16 1998-03-19 Koenig & Bauer Albert Ag Verfahren und Anlage zum automatischen Zu- und Abführen von Rollen
DE69728289T2 (de) 1996-11-12 2005-02-24 City Of Hope, Duarte Immunreaktive ctl-peptidepitope von humanem cytomegalovirus
GB9805477D0 (en) 1998-03-13 1998-05-13 Oxford Glycosciences Limited Methods and compositions for diagnosis of rheumatoid arthritis
US6858210B1 (en) 1998-06-09 2005-02-22 La Jolla Pharmaceutical Co. Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
IL125262A0 (en) 1998-07-07 1999-03-12 Yeda Res & Dev Synthetic peptides and pharmaceutical compositions comprising them
IL126447A (en) 1998-10-04 2004-09-27 Vascular Biogenics Ltd An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
WO2001088088A2 (en) 2000-05-18 2001-11-22 Hyseq, Inc. Novel nucleic acids and polypeptides
US6458953B1 (en) 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
AU5211200A (en) 1999-05-04 2000-11-17 Genethor Gmbh Method for diminishing specific immune reactions
CA2376057A1 (en) 1999-06-08 2000-12-14 La Jolla Pharmaceutical Company Valency platform molecules comprising aminooxy groups
AUPQ272699A0 (en) 1999-09-09 1999-09-30 Unisearch Limited Use of beta2GPI in diagnostic tests for autoimmune diseases
CN1399562A (zh) 1999-11-28 2003-02-26 拉卓拉药物公司 基于抗体亲和力来治疗狼疮的方法及使用这种方法的筛选方法和组合物
US20010051351A1 (en) 2000-03-27 2001-12-13 Racis Stanley Paul Antigen-specific immune complex-based enzyme-linked immunosorbent assay
US20020150898A1 (en) 2000-04-18 2002-10-17 Tang Y. Tom Novel nucleic acids and polypeptides
CA2414076A1 (en) 2000-06-08 2001-12-13 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
DE10048417A1 (de) 2000-09-29 2002-04-11 Roche Diagnostics Gmbh Verbindungen mit verzweigtem Linker

Also Published As

Publication number Publication date
US20050004351A1 (en) 2005-01-06
KR20010052713A (ko) 2001-06-25
JP2002517245A (ja) 2002-06-18
CN1310759A (zh) 2001-08-29
ES2275348T3 (es) 2007-06-01
EP1092027A1 (de) 2001-04-18
AU4339599A (en) 1999-12-30
EP1092027B1 (de) 2006-11-29
DE69934228D1 (de) 2007-01-11
US6858210B1 (en) 2005-02-22
PT1092027E (pt) 2007-02-28
CA2329942A1 (en) 1999-12-16
DE69934228T2 (de) 2007-10-04
WO1999064595A9 (en) 2000-09-08
AU772851B2 (en) 2004-05-06
WO1999064595A1 (en) 1999-12-16

Similar Documents

Publication Publication Date Title
DE69934228D1 (de) Domäne 1 beta2-gpi polypetiden und deren diagnostische und therepeutische verwendungen
ATE511849T1 (de) Peptide mit erhöhter bindungsaffinität für mindestens drei hla-a3-ähnliche moleküle
ATE428785T1 (de) Aktive und inactive cc-chemokinrezeptoren und nukleinsäuremoleküle, die für diesen rezeptor kodieren
DE69925805D1 (de) Skalierbare lösung für das wiederauffinden von bildern
DE19881091T1 (de) Material für Schleifkontakt, plattiertes Verbundmaterial und Gleichstrommotor kleiner Baugröße, der beides verwendet
DE69920641D1 (de) Skalierbare Gatekeepers in einem Internettelefoniesystem und Betriebsverfahren
FI956019L (fi) Eristettyjä peptidejä, jotka muodostavat komplekseja MHC-molekyyli HLA-C-klooni-10:n kanssa, ja niiden käyttö
NO974774D0 (no) Elektrisk drevet aktuator med feilsikker egenskap
DE60124678D1 (de) Proteingerüste für antikörper-mimetika und andere bindungsproteine
DE59005156D1 (de) Gleitbacke für Schiebedächer, Schiebehebedächer und dergleichen.
DE58904487D1 (de) Sitzelement zur reihenweisen anordnung.
FI963781A7 (fi) Eristettyjä, MAGE-3-peräisiä peptidejä, jotka kompleksoivat HLA-A2-mol ekyylejä, ja niiden käyttöjä
DE69700732D1 (de) Kurzschlussbrücke für einen elektrischen Steckverbinder und der entsprechenden Steckverbinder
IT1294723B1 (it) Snodo girevole omocinetico con serbatoio del lubrificante
TR23727A (tr) Oksimlerin ortadan kaldirilmasiyla sertlesen tek bilesenli polisiloksan rtv bilesimleri
DE69012674D1 (de) Untersuchungsgerät für Rohre.
DE69607121D1 (de) Gehäuse, insbesondere für elektrische Geräte
DE69834643D1 (de) Adipozyten-spezifische protein homologe
DE59106614D1 (de) Anordnung zur Verbindung von Sammelschienen.
DE69604376D1 (de) Verbindungsanordnung für elektrisches Gerät, insbesondere für ein verbindungsblockartiges Gerät, und ein mit solcher Anordnung ausgerüstetes Gehäuse
DE59807198D1 (de) Ultraschallwandler mit in wandlerlängsrichtung angeordneter platine für eine elektrische schaltung
DE69729497D1 (de) Zerstörungsfreie Röntgenstrahlungsuntersuchung für die Nahrungsmittelindustrie
DE69507504D1 (de) Dichtungseinheit,insbesondere für elektrische verbinder
DE69005294D1 (de) Schienenlager.
DE58908137D1 (de) Leuchtscheibe für durchleuchtungsfähige Vorlagen, wie Dias und dgl.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1092027

Country of ref document: EP

EEIH Change in the person of patent owner